Michael Anthony Rodríguez-Rivera

Mr. Michael Anthony Rodríguez-Rivera


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2024 in Cancers
Verified
Journal Article
Open access
PDF file
JDJennifer Díaz-Rivera
Jennifer Díaz-Rivera
MRMichael Anthony Rodríguez-Rivera
Michael Anthony Rodríguez-Rivera
Natalie M. Meléndez-VázquezNatalie M. Meléndez-Vázquez
Natalie M. Meléndez-Vázquez
FGFilipa Godoy-Vitorino
Filipa Godoy-Vitorino
Stephanie Dorta-EstremeraStephanie Dorta-Estremera
Stephanie Dorta-Estremera
The United States is suffering from an epidemic associated with high-risk strains of the Human Papillomavirus (HPV) predominantly responsible for the development of head and neck squamous cell carcinoma (HNSCC). Treatment with immune checkpoint inhibitors targeting programmed death 1 (PD-1) or its ligand PD-L1 has shown poor efficacy in HNSCC patients, observing only a 20–30% response. Therefore, biological marker identification associated with PD-1 blockade response is important to improve prognosis and define novel therapeutics for HNSCC patients. Therapy response was associated with increased frequencies of activated CD27+T cells, activated CD79a+ B cells, antigen-presenting CD74+ dendritic and B cells, and PD-L1+ and PD-L2+ myeloid-derived suppressor cells (MDSCs). The oral microbiota composition differed significantly in mice bearing tongue tumors and treated with anti-PD-1. A higher abundance of Allobaculum, Blautia, Faecalibacterium, Dorea, or Roseburia was associated with response to the therapy. However, an increase in Enterococcus was attributed to tongue tumor-bearing non-responding mice. Our findings indicate that differences in immune phenotypes, protein expression, and bacterial abundance occur as mice develop tongue tumors and are treated with anti-PD-1. These results may have a clinical impact as specific bacteria and immune phenotype could serve as biomarkers for treatment response in HNSCC.